Soon after Integra’s optimistic conference call, they announced positive results of the clinical trials for INTEGRA Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers. Integra expects to submit their data from these trials to the FDA by the end of 2014 and to commercialize the product in 2016.
Going forward, Integra estimates FY2014 revenues to be between $920 and $940M, and FY EPS to be between $1.06 and $1.24. Our investment thesis for Integra remains bright. Since our buy-in price of $40.41, UASBIG has realized an upside of over 23.75%.